Ipinzan

Metformin Hydrochloride / Vildagliptin, the active ingredient in Ipinzan, is a Biguanide / DPP‑4 inhibitor presented as a fixed‑dose tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control fasting and post‑prandial blood glucose levels while improving overall glycaemic control.

GNH USA supplies Ipinzan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide across multiple regions. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Ipinzan, a fixed‑dose combination of metformin and vildagliptin, is used in the management of type 2 diabetes mellitus and related therapeutic pathways. - Type 2 diabetes mellitus: improves overall glycaemic control by lowering fasting and post‑prandial glucose levels. - Inadequate control on metformin monotherapy: adds DPP‑4 inhibition to achieve additional HbA1c reduction. - Early-stage type 2 diabetes in adults: assists in reaching target blood glucose when lifestyle measures alone are insufficient.

Ipinzan may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Gastrointestinal upset (nausea, abdominal discomfort, diarrhea). - Headache. - Upper respiratory tract infection.

Serious or Rare Side Effects: - Lactic acidosis (rare but potentially fatal). - Severe hypoglycemia, especially when combined with insulin or sulfonylureas. - Pancreatitis. - Anaphylactic reactions.

When prescribing Ipinzan, several precautions should be observed to ensure patient safety. - Renal function assessment: evaluate creatinine clearance before initiation and periodically during therapy. - Hepatic function monitoring: avoid use in patients with significant liver disease due to risk of lactic acidosis. - Cardiovascular status: use cautiously in patients with congestive heart failure or unstable cardiac conditions. - Elderly patients: start at lower dose and monitor for accumulation and adverse effects. - Drug interactions: review concomitant medications that may affect renal clearance or increase hypoglycemia risk. - Store at room temperature: keep tablets in the original container, protect from moisture and light.

Ipinzan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing metformin accumulation. - Insulin or sulfonylureas: combined use can cause severe hypoglycemia. - Cimetidine: can raise metformin plasma concentrations, increasing risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen, naproxen): may impair renal function, affecting metformin clearance. - Diuretics (e.g., thiazides, loop diuretics): can reduce renal perfusion and increase metformin levels. - ACE inhibitors or ARBs: monitor renal function and electrolytes when used together.